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Abstract
Background: Although metabolism is profoundly altered in human liver cancer, the extent to which experimental
models, e.g. cell lines, mimic those alterations is unresolved. Here, we aimed to determine the resemblance of
hepatocellular carcinoma (HCC) cell lines to human liver tumours, specifically in the expression of deregulated
metabolic targets in clinical tissue samples.
Methods: We compared the overall gene expression profile of poorly-differentiated (HLE, HLF, SNU-449) to
well-differentiated (HUH7, HEPG2, HEP3B) HCC cell lines in three publicly available microarray datasets. Three
thousand and eighty-five differentially expressed genes in ≥2 datasets (P < 0.05) were used for pathway enrichment
and gene ontology (GO) analyses. Further, we compared the topmost gene expression, pathways, and GO from poorly
differentiated cell lines to the pattern from four human HCC datasets (623 tumour tissues). In well- versus poorly
differentiated cell lines, and in representative models HLE and HUH7 cells, we specifically assessed the expression
pattern of 634 consistently deregulated metabolic genes in human HCC. These data were complemented by
quantitative PCR, proteomics, metabolomics and assessment of response to thirteen metabolism-targeting
compounds in HLE versus HUH7 cells.
Results: We found that poorly-differentiated HCC cells display upregulated MAPK/RAS/NFkB signaling, focal adhesion,
and downregulated complement/coagulation cascade, PPAR-signaling, among pathway alterations seen in clinical
tumour datasets. In HLE cells, 148 downregulated metabolic genes in liver tumours also showed low gene/protein
expression – notably in fatty acid β-oxidation (e.g. ACAA1/2, ACADSB, HADH), urea cycle (e.g. CPS1, ARG1, ASL),
molecule transport (e.g. SLC2A2, SLC7A1, SLC25A15/20), and amino acid metabolism (e.g. PHGDH, PSAT1, GOT1, GLUD1).
In contrast, HUH7 cells showed a higher expression of 98 metabolic targets upregulated in tumours (e.g. HK2, PKM,
PSPH, GLUL, ASNS, and fatty acid synthesis enzymes ACLY, FASN). Metabolomics revealed that the genomic portrait
of HLE cells co-exist with profound reliance on glutamine to fuel tricarboxylic acid cycle, whereas HUH7 cells use
both glucose and glutamine. Targeting glutamine pathway selectively suppressed the proliferation of HLE cells.
Conclusions: We report a yet unappreciated distinct expression pattern of clinically-relevant metabolic genes in HCC cell lines,
which could enable the identification and therapeutic targeting of metabolic vulnerabilities at various liver cancer stages.
Keywords: Omics, Tumour metabolism, Well-differentiated, Poorly differentiated, Metabolic vulnerability, Selective
therapy, Biomarkers, MAPK/Ras signaling, Hepatocellular carcinoma
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Background
Hepatocellular carcinoma (HCC) is the most common
type of liver cancer, which also include cholangiocarci-
noma as well as secondary liver cancer that metastasized
from distant organ-sites, e.g. colon and pancreas. HCC
is a highly heterogeneous and poorly understood tumour
entity. While a lot of its molecular alterations, e.g. TP53,
TERT promoter and CTNNB1 mutations are well known
[1, 2], the clinical benefit of exploiting these genes has
not been well proven. Similarly, reliable predictive bio-
markers of HCC are currently lacking. Drug resistance
is also a major challenge in HCC, and has contributed to
the failure of over 7 phase III clinical trials [3].
Similar to human HCC, the corresponding cell lines
used for in vitro studies are heterogeneous in their mo-
lecular and phenotypic portraits. For example, HCC cell
lines show differential proliferative response to Src/Abl
inhibitor dasatinib [4] as well as transforming growth
factor beta (TGF-β) stimulation [5, 6]. HCC cell lines
also show dissimilar expression levels of many known
cancer-associated proteins such as caveolin-1 (CAV1),
alpha fetoprotein (AFP), and WNT signaling molecules
[7–9]. Such distinct molecular and phenotypic back-
ground, which is also seen in cell lines of other cancer
types, often raise the question of the extent to which cell
lines mimic (or “recapitulate”) original human tumour
profile. Although cancer cell lines are not necessarily
original tumours – given the unphysiological culture
conditions in which they are often maintained in vitro –
numerous studies including the cancer cell line
encyclopedia (CCLE) [10] and COSMIC projects [11]
have found clinically meaningful similarities between cell
lines and human tumours. In fact, despite the bourgeon-
ing interest in the use of alternative models (e.g. orga-
noids, mice), human cancer cell lines will for a long time
remain the most readily accessible options for under-
standing the molecular basis of oncogenesis. Cell
lines have notably proven to be useful for testing drug
efficacy [10] and identifying synthetic lethality [12].
Therefore, a thorough characterization of the shared
molecular signatures between HCC cell lines and the
counterpart primary tumours is highly needed for defin-
ing core and novel alterations that can be investigated in
vitro with the highest prospect of clinical translation.
We recently identified 284 metabolic genes upregu-
lated in at least 6 of 8 human HCC microarray datasets,
and also 350 downregulated metabolic genes under the
same criteria. Two hundred and one of these genes were
highlighted as predictive of overall survival in a cohort
of HCC patients, underscoring the potential clinical sig-
nificance of the genes [13]. Here, we investigated
whether the expression pattern of those human HCC
tissue-derived metabolic genes (herein called HMGs) is
reflected in HCC cell lines, especially those poorly
differentiated and known to be representative of more
advanced HCC stage. By complementing the gene data
with proteomics, metabolomics, and phenotypic re-
sponse to metabolism-targeting drugs, we have uncov-
ered pathway alterations that are shared or distinct
between human HCC cell lines and the corresponding
tumour tissues.
Methods
Determination of the genomic pattern of human HCC
tissues and cell lines
Microarray datasets GSE36133 (from CCLE project)
[10], GSE35818 [4] as well as GSE57083 were used for
comparing differential gene expression in human HCC
cell lines. In each dataset, NCBI GEO2R tool was used
to analyse the profile of HLE, HLF, and SNU-449 cells
(poorly differentiated) relative to HUH7, HEPG2, and
HEP3B cells (well-differentiated). Thereafter, the re-
sults were downloaded and the differentially expressed
genes (P < 0.05) were separated into two categories – i.e.
the upregulated and downregulated genes in poorly dif-
ferentiated cell lines. Using Venn diagram tool (http://
bioinfogp.cnb.csic.es/tools/venny/), genes exclusively up-
regulated or downregulated in ≥2 datasets (unless other-
wise indicated) were selected for comparison with
human HCC tissues genomic profile. Comparison with
human HCC profile was in three parts. First, examining
how the topmost 100 significantly upregulated or down-
regulated genes in all three cell line datasets are
expressed in four patients datasets (GSE14520,
GSE25097, GSE1898, and GSE55092). Second, examin-
ing the cell lines' expression of previously published list
of consistent metabolic genes (n = 284 upregulated and
350 downregulated HMGs) that were derived from ≥6
human HCC microarrays, including GSE14520 (used in
this study) [13]; and third, comparative analysis of
the ontology of all genes consistently upregulated or
downregulated in the four patients datasets (P < 0.05)
and in ≥2 cell line datasets (P < 0.05). The second and
third parts are discussed next. For the first part, the
z-score of expression fold was calculated for each human
HCC dataset. Then, the topmost genes identified from
cell line data were extracted from each human dataset,
and subsequently ranked by their average z-score across
the four human datasets. With the + or – z-score values
determined for each gene in all four human datasets, a
gene significantly upregulated/downregulated in poorly
differentiated HCC cell lines and upregulated/downregu-
lated in the human datasets were considered to be con-
cordantly expressed in both settings. In contrast, all
genes significantly upregulated in poorly differentiated
cell lines, but downregulated in tumours, and vice versa,
were considered to be discordant (in other words, are
more mimicked by well-differentiated HCC cell lines).
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Identification of altered human HCC metabolic genes
mimicked by cell lines
To uncover the HMGs mimicked by the HCC cell lines,
all genes significantly expressed in ≥2 of the earlier men-
tioned cell line datasets were overlapped with the 284
upregulated and 350 downregulated HMGs. This was
followed by the selection of specific metabolic genes
concordantly upregulated/downregulated in poorly dif-
ferentiated cell lines as those more mimicked by the
more ‘cancer-like’ cell lines. On the other hand, HMGs
with discordant or opposite expression pattern were
considered to be more portrayed by well-differentiated
cell lines. In addition, HMGs expression was analyzed,
focusing on HUH7 and HLE (two cell lines we mainly
used for subsequent phenotypic assays). Specifically,
gene expression data for these two cell lines were ob-
tained via ArrayExpress database (https://www.ebi.ac.uk/
arrayexpress/) for GSE57083, and cBioPortal platform for
the CCLE project. Differences in measured mRNA (i.e.
HLE - HUH7) were used to determine the relative expres-
sion of HMGs by the respective cell lines in each dataset.
Subsequently, HLE cells were considered to mimic the
up- or downregulated HMGs it concordantly express at
a higher or lower level in both datasets. HMGs that
showed discordant expression pattern in both datasets are
more mimicked by HUH7 cells.
Pathway enrichment and gene ontology analyses
Pathway enrichment and gene ontology (GO) analysis
were performed using the bioinformatics platform DA-
VID 6.8 (https://david.ncifcrf.gov/). For human HCC
microarrays, we have previously shown pathway enrich-
ment [13] and so only GO analysis was performed in
this current study. For this, the significantly upregu-
lated (n = 2017) or downregulated (n = 1547) genes in all
four human HCC datasets were separately analysed to de-
termine their associated molecular function (MF), cellular
component (CC) and biological process (BP). For the cell
lines, pathway enrichment and GO analysis were per-
formed using genes upregulated or downregulated in
poorly differentiated HCC cell lines (at least in two data-
sets). Based on P < 0.0001 and false discovery rate (FDR) <
25%, the topmost 10 enriched pathways as well as top five
MF, CC, and BP were selected.
Cell culture
Human HCC cell lines HUH7, HEPG2, HLF and HLE
were obtained from the Japanese Cancer Research Re-
sources Bank or American Type Culture Collection. The
cells were cultured at 37 °C in a humidified incubator
with 5% CO2. Unless otherwise stated, cells were main-
tained in Dulbecco Modified Eagle’s medium (DMEM,
High glucose, Lonza, BE12–709) supplemented with
2 mM glutamine (Gln), 10% heat inactivated fetal bovine
serum, penicillin (100 U ml− 1), and streptomycin
(100 μg ml− 1). For glucose or glutamine deprivation
experiments, the cells were first seeded into culture
plates and incubated overnight. Thereafter, the cells
were washed 1× with Hank’s Balanced Salt Solution
followed by further incubation with culture media
lacking the respective metabolites. Compounds used
to interfere with metabolism in the cell lines are listed in
the Additional file 1: Methods.
Proteomics
For proteomic comparison, HUH7 and HLE cells were
seeded at a density of 5 × 105 in 6 well plates (7 replicate
wells for HUH7 and 8 for HLE). The cells were cultured
for 48 h. Thereafter, culture media was aspirated off and
the cells were washed by gentle swirling with 3 ml phos-
phate buffered saline per well. This step was repeated
twice, after which cells were detached by scraping, and
transferred into 1.5 ml vials. The cell suspension was
then centrifuged at 800 rpm for 5 min at 4 °C and the
supernatant discarded. The remaining cell pellets were
stored at − 80 °C until analysis. Proteomic analysis was
conducted by mass spectrometry as previously described
[14]. Proteins with at least two unique peptides and FDR
adjusted P < 0.05 after analysis of variance were consid-
ered significant in our analyses, which includes pathway
enrichment, GO, and overlap with HMGs.
Statistics and other analyses
Statistical significance was accepted as P < 0.05, unless
otherwise indicated. Where applicable, results were
expressed as mean ± standard deviation (SD). Data were
analysed with GraphPad Prism v6 (La Jolla, USA). Gene-
cards database (http://www.genecards.org) was used for
crosschecking gene names and functions. The differen-
tially expressed genes in human HCC microarrays
GSE14520, GSE25097, GSE1898, and GSE55092 were de-
termined by using NCBI GEO2R, comparing normal
liver/adjacent non-tumours versus liver tumours. Informa-
tion about metabolomics and other experiments per-
formed with the cell lines are included in the Additional
file 1: Methods.
Results
Poorly differentiated HCC cell lines are phenotypically
more ‘cancer-like’ and possess tumour molecular portraits
To identify human HCC metabolic gene patterns dis-
tinctly mimicked in vitro – the correlated proteomic and
metabolite-level alterations, as well as cell-specific re-
sponse to targeting metabolism – we started with com-
paring the genomic profile of six frequently used
human HCC cell lines (Fig. 1a). Noteworthy, three of the
cell lines (HUH7, HEPG2, and HEP3B) have epithelial
features and represent early (well-differentiated) HCC
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stage, whereas the others (HLE, HLF, and SNU-449) are
poorly differentiated late-stage models with mesenchymal
cell properties [5, 9]. Importantly, these HCC cell lines are
known to differ in cancer properties, with the poorly
differentiated cells having higher proliferative and migra-
tory phenotypes [4–9]. We confirmed that representative
poorly differentiated cell line HLE has higher migration
capacity compared to the well-differentiated cell HUH7
Fig. 1 Molecular characterization of the resemblance between HCC cell lines and human liver tumours. a Workflow of analyses to unravel the
metabolic profiles of HCC cell lines. *published list of metabolic genes consistently deregulated in 6–8 human HCC microarray datasets [13].
b Venn diagram showing the number of differentially expressed genes in poorly differentiated cell lines (HLE, HLF, SNU-449) relative to well-
differentiated cell lines (HUH7, HEPG2, HEP3B), in three cell line microarray datasets (P < 0.05). c Heatmap showing genes within the top 100
upregulated or downregulated in all three cell line datasets, GSE36133, GSE35818, and GSE57083 (adjusted P < 0.0001) and their expression
pattern in patients datasets (P < 0.05). Below are four human HCC datasets used for assessing resemblance with the cell line profile. The genes
were ranked based on their average z-score in the human datasets. Diff. – differentiated. d Heatmap showing 36 HCC-associated genes
differentially expressed in the poorly differentiated cell lines (P < 0.05 at least in one cell line dataset), and their expression pattern
(z-score ranked) in patients datasets . Red – upregulated; green – downregulated; blank – not significant or no data available. e Top 10
proteins distinctly expressed in the representative well (HUH7) and poorly differentiated cell line (HLE). ≥2 peptides were detected by mass
spectrometry for the indicated proteins, FDR adjusted P < 0.0001. Bars show mean ± SD of the expression of each protein in one of the cell lines
compared to the other. Replicate samples n = 7 for HUH7 and 8 for HLE cells: a.u – arbitrary unit. f Quantitative PCR validation of a panel of genes
derived from the topmost altered candidates in cell line datasets and or proteomics data. Bars show mean ± SD of triplicate samples
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using FluoroBlok and in vitro scratch assays (Additional
file 1: Figure S1a). Consistent with having more cancer
features, intracellular adenosine triphosphate (ATP) – a
metabolic readout positively associated with cell migration
[15] – is also higher in poorly differentiated cell lines
(Additional file 1: Figure S1b). To determine the genomic
profile of the poorly differentiated relative to
well-differentiated cell lines, we used three publicly avail-
able microarray datasets GSE57083, CCLE, and GSE35818
(Fig. 1a–d). We derived 3085 significantly expressed genes
(n = 1584 upregulated and 1501 downregulated, P < 0.05)
in at least two of the three datasets (Additional file 2:
Table S1). Interestingly, within the top 100 upregulated, or
downregulated genes in all three datasets were core candi-
dates similarly upregulated (n = 34) or lowly expressed (n =
46, adjusted P < 0.0001) in poorly differentiated cell lines
(Fig. 1c). Thus, with > 30% overlap within the top 100
genes, we considered these microarray datasets to be highly
reproducible.
We therefore used the 34 upregulated and 46 down-
regulated genes to interrogate the resemblance in ex-
pression pattern between the cell lines and human HCC
tissues from four datasets (total: 635 controls versus 623
tumour samples). Intriguingly, where significantly al-
tered, more than half of the top upregulated genes in the
cell lines (e.g. RFTN1, TFPI2, AXL, BASP1, C-C motif
chemokine ligand 2, CCL2) were downregulated in most
human HCC microarrays (Fig. 1c), suggesting a discord-
ance in molecular expression in vitro for several upregu-
lated genes in human HCC. Nevertheless, poorly
differentiated cell lines mimicked upregulated expression
of genes (in tumours) such as CAV1, COL4A1, and novel
candidates such as TSPAN5, TENM2, C15orf48, PLAU,
AHNAK2, FAM129A, PLAU and platelet-specific phos-
phofructokinase (PFKP) (Fig. 1c). In the downregulated
gene category, human HCC profile was strongly mim-
icked by about 40 of the 46 identified genes (Fig. 1c), in-
cluding fatty acid binding protein 1 (FABP1), TTR,
EPCAM, apolipoproteins (APOA1/2, APOB, APOC1/3,
APOE), MTTP, complement 3 and 5 (C3/C5), among other,
reflecting ~ 85% concordance with patients’ tumour sam-
ples. The notable exemptions were villin 1 (VIL1), VSNL1,
MBNL3, KLB, AFP and glypican 3 (GPC3), which are all
consistently upregulated in liver tumour datasets. It is note-
worthy that while many of these downregulated genes are
novel candidates in HCC (Fig. 1c), AFP and GPC3 are often
considered clinical biomarkers in HCC [16].
Next, we compiled a list of genes (n = 82, Additional file 3:
Table S2) associated with human HCC. These, for in-
stance, include candidate drivers, genes expressed by
distinct proliferation subclasses or involved in epithelial–
mesenchymal transition (EMT). Using this list, we asked
which ‘HCC-associated’ genes can clearly distinguish poorly
differentiated HCC cell lines from those well-differentiated,
and also reflect a gene-level resemblance of the former to
liver tumour tissues. Of the ‘HCC-associated’ gene list, 36
(44%) were differentially expressed (P < 0.05 at least in one
dataset) in poorly differentiated cell lines relative to those
well-differentiated. Examples are mitogen-activated protein
kinase (MAPK)/RAS family members (HRAS and NRAS),
hemochromatosis (HFE), BRD7, ATM, vimentin (VIM),
which are upregulated in poorly differentiated cell lines and
in human HCC datasets (Fig. 1d). Other upregulated genes
such as PTEN, ZEB2, STAT3 and IL1B did not align with
tumour expression pattern as they are consistently down-
regulated in the patients datasets.
Several ‘HCC-associated’ genes downregulated in poorly
differentiated cell lines showed the opposite expression pat-
tern in tumours. For example, besides e-cadherin (CDH1),
FAH, PNPLA3, GSTT1, ATP7B, SERPINA1, NFE2L2, CUL3
and MDM2 (all downregulated both in poorly differ-
entiated cell lines and tumours), the other ‘HCC-asso-
ciated’ genes such as FRK, HNF1A, ARID1B, KEAP1,
β-catenin (CTNNB1), FGF19, LGR5 and glutamine
synthetase (GLUL) were lowly expressed in poorly
differentiated cell lines (i.e. more expressed in well-
differentiated cells) and consistently upregulated in
human liver tumours (Fig. 1d). Using HUH7 and HLE
cell lines, we performed mass spectrometry-
based proteomics and identified novel targets that
clearly distinguish the two cell types (e.g. GCHFR,
MAN1A1, APOA1, > 25 fold more expressed in HUH7
cells and BASP1, SLC25A12, CRIP2, CPT1A, CD59,
AFAP1, LGALS3BP, > 50 fold more expressed in HLE cells
at P < 0.0001) (Fig. 1e). The encoding genes of some of
the proteins were validated by qPCR method (Fig. 1f ),
and showed a consistent expression pattern with the hu-
man tumour datasets (Additional file 1: Figure S1c). In im-
munoblotting and qPCR analyses, poorly differentiated
cell lines also showed more resemblance to expected
tumour profile based on their expression of known targets
such as CDH1, VIM, CAV1, PKM2, pERK, mitochondrial
pyruvate carrier 1 (MPC1), and matrix metalloproteinase 9
(Additional file 1: Figure S1d–e). Taken together, these data
support that poorly differentiated HCC cell lines are more
cancer-like in their molecular and phenotypic profiles.
Molecular profiling reveals a strong overlap in metabolism
between poorly differentiated HCC cell lines and human
liver tumours
To identify the specific pathways to which the genes
more or less expressed in the poorly differentiated HCC
cell lines belong, we used the 1584 upregulated and
1501 downregulated genes for enrichment analysis in
DAVID (https://david.ncifcrf.gov). Pathway enrichment
of the upregulated genes indicated an activation of can-
cer pathways, MAPK/RAS pathway, focal adhesion, pro-
teoglycans in cancer, nuclear factor kappa B signaling
Nwosu et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:211 Page 5 of 15
and tumour necrosis factor signaling (Fig. 2a). Examples
of genes involved in these pathways are CAV1/2, TGFB2,
SMAD2/3, WNT5A/B, JUN, FGF1/3/5, MAPK10/11,
HRAS, NRAS, RRAS, IRAK1, etc (Additional file 4: Table
S3a). This pathway enrichment pattern is consistent with
our previous observation in eight human HCC microarray
datasets[13]. Further, as observed in human HCC microar-
rays, the upregulation of cancer pathways in the poorly dif-
ferentiated cell lines co-existed with the predominant
downregulation of metabolic pathways – along with
complement/coagulation cascade and peroxisome
proliferator-activated receptor (PPAR) signaling (Fig. 2a,
Additional file 4: Table S3b). However, our prior study did
not analyse HCC gene ontology (GO) [i.e. molecular func-
tion, MF; cellular component, CC and biological process,
BP]. Thus, to compare GO between the cell lines and tu-
mours, we first separately overlapped upregulated or down-
regulated genes in the four human HCC datasets
mentioned earlier (Additional file 1: Figure S2a). This led
to the generation of a list of core genes upregulated in all
Fig. 2 Functional annotation analysis, metabolic gene and proteomic profile of HCC cell lines. a Topmost pathway enrichment of genes upregulated
(n = 1584) or lowly expressed (n = 1501) in poorly differentiated relative to well-differentiated HCC cell lines. P < 0.05 in 2–3 of the cell line datasets.
Analysis was performed with DAVID v6.8, reference: Kyoto Encyclopedia of Genes and Genomes (KEGG). HTLV – Human T-lymphotropic virus, NFkB –
nuclear factor kappa B, PPAR – peroxisome proliferator-activated receptor, TNF – tumor necrosis factor. b Topmost gene ontology (GO) for genes
(n = 1547) consistently downregulated in all 4 human HCC microarrays datasets (GSE14520, GSE25097, GSE1898, GSE55092), compared to the GO
profile of poorly differentiated cell lines. # - number of (genes). ER – Endoplasmic reticulum, HDL – high density lipoprotein, PM – plasma membrane,
‘Neg. – negative’ ‘Transcript.’ – transcriptional, ‘reg.’ – regulation. c Venn diagram showing human HCC tissue-derived metabolic genes (HMGs)
expressed concordantly (i.e. mimicked) or discordantly by the poorly differentiated cell lines (2–3 datasets, P < 0.05). ↑ – upregulated; ↓ –
downregulated. Note: the discordant genes are more mimicked by well-differentiated cell lines. A full list of the 92 concordant ↓ HMGs are contained
in Additional file 6: Table S5. d Topmost pathway enrichment of proteins more expressed in HUH7 or HLE cells (FDR adjusted P < 0.05). e 20 most
highly or lowly expressed HMGs-encoded proteins in the cell lines (FDR adjusted P < 0.05, mean fold difference > 2, HUH7 = 7, HLE = 8 samples).
Arrows point to their encoding gene expression pattern in human HCC tissues. ● expressed in HCC in the opposite direction to the arrows
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four human datasets (e.g. GPC3, AKR1B10, AFP, ACSL4,
RRM2, CDK1, IGF2BP3, DKK1, TXNRD1, SOX4, etc, n=
2017), as well as those consistently downregulated, e.g.
liver-specific glutaminase (GLS2), complement 7 and
9 (C7/9), CXCL12, CYP1A2, CYP2E1, GYS2, HAMP,
IGF1, LCAT, SLC22A1, etc, n = 1547) (Additional file 5:
Table S4). Of note, AKR1B10, ACSL4, GLS2, LCAT,
were among the metabolic targets we previously iden-
tified as consistent in HCC [13], indicating a high al-
teration frequency of these genes across liver cancer
datasets.
GO of upregulated genes in human HCC or poorly
differentiated cell lines showed substantial overlaps, i.e.
common MF = 8, CC = 14, and 8 in BP (FDR < 25%). MF
protein binding and cell adhesion-related activities, CC
nucleoplasm and cytoplasm, as well as virus-related BP
were within the top five of the respective GO terms for
the human and cell line datasets (Additional file 1:
Figure S2b). The GO derived with downregulated genes
showed a much stronger concordance between tumours
and the poorly differentiated cell lines (common MF = 13,
CC = 19, and 38 in BP, FDR < 25%). Metabolic activities
emerged as the most prominently mimicked alterations in
the cell line and human HCC data (Fig. 2b). MF protein,
fatty-acyl-CoA and flavin adenine dinucleotide binding,
CC extracellular exosome and mitochondrial matrix, BP
cholesterol metabolism and its transport activities (lipo-
protein metabolic process) were the topmost or shared
GOs (Fig. 2b). A striking BP in tumours that did not
similarly manifest in poorly differentiated cell line
data is ‘inflammatory response’, which may be due to
the absence of tumour immune microenvironment in
cell culture.
Next, we focused on metabolic genes. To our know-
ledge, the extent to which consistently altered metabolic
genes in human HCC tissues (i.e. HMGs) are concor-
dantly expressed by the surrogate cell lines has not yet
been reported. We identified HMGs whose expression
pattern are more mimicked by poorly differentiated
HCC cell lines. These include 92 of 350 downregu-
lated HMGs (Fig. 2c, see Additional file 6: Table S5).
In addition, 31 of 284 upregulated HMGs showed
higher expression in the poorly differentiated cell
lines as expected, but we also found 30 HMGs with
discordant expression pattern (Fig. 2c). Of note, the
genes not mimicked by poorly differentiated cell lines
show concordant pattern in well-differentiated cell lines as
in human HCC microarrays. In addition, while poorly dif-
ferentiated cell lines mimicked mostly the downregulated
HMGs, the upregulated HMGs showed more consistency
in well-differentiated cell lines. We further interro-
gated the proteomic data from HUH7 and HLE cells, fo-
cusing on proteins for which at least two peptides were
detected and have FDR adjusted P < 0.05 (Additional file 7:
Table S6). Pathway enrichment of the proteins more
expressed in HLE cells (n = 797) was cancer-oriented al-
beit heterogeneous (Fig. 2d). In contrast, the proteins less
expressed in HLE cells though lower in number (n = 616)
were strongly involved in metabolic processes as observed
with genomic data. Thus, at proteomic level, the poorly
differentiated cell lines also strongly mimic the downregu-
lation of metabolic components as seen in tumours. Car-
bon metabolism surprisingly appeared in the pathway
enrichment of proteins more expressed as well as those
lowly expressed in HLE cells (Fig. 2d). However, the spe-
cific proteins involved were a heterogeneous mixture of
enzymes in glycolysis, tricarboxylic acid (TCA) cycle and
amino acid metabolism (discussed latter).
In line with the notion that the metabolic gene profile
of the cell lines is reflected at the protein level, the ex-
pression pattern of the top deregulated ‘metabolic pro-
teins’ in HLE relative to HUH7 cells (fold difference > 2)
overlapped with that of the encoding HMGs (Fig. 2e).
For example, 17 of the top 20 upregulated metabolic
proteins in HLE cells (except NNMT, HMGCL ACAT1),
and 16 of the top 20 downregulated proteins (except
HK2, PSPH, CKB, PYCR1) (Fig. 2e) are candidates
whose corresponding HMGs are up- or downregulated,
respectively. The exemptions, i.e. NNMT, HK2, etc.,
were expressed in HUH7 cells as in human HCC tissues,
indicating that the well-differentiated cell lines also dis-
play tumour metabolic gene expression pattern at pro-
tein level (Additional file 1: Figure S3). Altogether,
pathway enrichment, GO, and expression of specific
metabolic genes or proteins underscore a strong overlap
in signaling and metabolic processes between poorly dif-
ferentiated HCC cell lines and clinical tumour data.
HCC molecular alterations mimicked in the poorly
differentiated cell lines include downregulated
components of β-oxidation, urea cycle, molecule transport,
and amino acid processes
It is noteworthy that some metabolic genes , though dif-
ferentially expressed between well- and poorly differenti-
ated cell lines, were at protein level not distinctly
expressed in HLE compared to HUH7 cells. Examples
are RRM1, RRM2, PAICS, ITPA, PPAT and GART (in
nucleotide biosynthesis) and PGLS, TALDO1 and DERA
in the pentose phosphate pathways (PPP). Along with
these were over 20 candidates in ribosomal protein syn-
thesis (Additional file 7: Table S6), suggesting that such
indistinct expression level could be due to the overabun-
dance of these proteins in the cell lines. To determine the
specific metabolic processes represented by deregulated
HMGs in HLE relative to HUH7 cells, we overlapped their
distinctly expressed HMGs with those up- or downregu-
lated in human HCC datasets (Fig. 3a–b). Consistent with
the comparison of three well- versus poorly differentiated
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cell lines in general (shown in Fig. 2c), there was a strong
overlap in the expression pattern of downregulated HMGs
in HLE cells. Specifically, 137 downregulated HMGs
emerged as also lowly expressed in HLE cells (Fig. 3b).
With upregulated HMGs, HUH7 cells showed a stronger
resemblance to tumours as it expressed 78 candidates at a
higher level compared to 48 candidates more expressed in
HLE cells (Fig. 3a). Indeed, combined with proteomics data,
148 downregulated or 79 upregulated HMGs were similarly
low or highly expressed by HLE cells, whereas 42 and 98,
respectively, were expressed byHUH7 cells (Additional file 8:
Table S7). These data confirm our earlier observation
(shown in Fig. 1) that some genes identified in human HCC
are more similarly expressed in the well-differentiated cell
lines than in the more ‘cancer-like’ groups.
Next, we assigned the individual genes to their re-
spective biochemical pathways, as in our prior study
[13]. Across multiple metabolic pathways, several upreg-
ulated HMGs were collectively more expressed in
HUH7 cells (Fig. 3a). For example, in glycolysis, hexoki-
nase domain containing 1 (HKDC1), hexokinase (HK1),
PFKP, PGK1, ENO1, and lactate dehydroge-
nases (LDHA/B) are more expressed in HLE cells, but
glucose transporter 6 (SLC2A6), hexokinase muscle iso-
form (HK2), ALDOA, BPGM, pyruvate kinase (PKM),
DLAT, and MPC2 are upregulated HMGs more
expressed in HUH7 cells. Similarly, asparagine synthe-
tase (ASNS), glutamine transporters (SLC1A3, SLC1A4),
FASN in fatty acid synthesis (lipogenesis), and PSPH (in
serine pathway) are all expressed higher in HUH7 cells.
Furthermore, yet unknown but consistently upregulated
HMGs such as PLCB1, GNPAT, PLA2G7 and CDS1 in
membrane lipids, as well as ALG3, B3GALNT1, CHPF2,
DOLK and LYZ in glycan metabolism are more
expressed in HUH7 cells. Other upregulated meta-
bolic genes that showed higher expression in HUH7
cells include NADPH oxidase 4 (NOX4), phosphogluco-
nate dehydrogenase (PGD in PPP) and AKR1B10 (among
Fig. 3 The collective representation of human HCC metabolic gene pattern by liver cancer cell lines. a Distribution of upregulated HMGs similarly more
expressed in either HUH7 or HLE cells across metabolic processes. b Distribution of downregulated HMGs similarly less expressed in either HUH7 or HLE
cells across metabolic processes. Generated based on consistent expression pattern in both GSE57083 and CCLE datasets. ‘Others’ – metabolic processes
beyond those shown. S.M. – small molecules, TCA – tricarboxylic acid, OXPHOS – oxidative phosphorylation, PPP – pentose phosphate pathway. c Specific
HMGs more mimicked by HUH7 or HLE cell lines in selected metabolic processes . *showed similar expression pattern in proteomics. d Amino
acid-associated HMGs that showed low expression in HLE cells, or high expression (↑/red) in HUH7, as in patients datasets. BCAAs – branched
chain amino acids
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the topmost upregulated metabolic gene in human HCC
datasets), as well as key players in cholesterol metabol-
ism (e.g. SQLE, FDPS, IDI1) and TCA cycle (e.g. MDH2,
IDH1/2, IDH3A/B, FH, ME1/2) (Additional file 8: Table
S7). These observations reveal known and novel meta-
bolic genes in cancer that are more similarly expressed
in a well-differentiated HCC cell line.
We observed an overwhelming consistency with hu-
man HCC data when considering downregulated HMGs
also lowly expressed in HLE cells (Fig. 3b). Alterations
in fatty acid metabolism (mainly β-oxidation), urea cycle,
molecule transporters, and amino acid processes
emerged as the most collectively represented in HLE
cells. For instance, half of over 30 downregulated HMGs
in fatty acid metabolism, e.g. ACAA1/2, ACADSB,
HADH, ACADL, CPT2 and lipases (LIPC/G), are low in
HLE cells as in human HCC datasets (Fig. 3c). In urea
cycle, of the 5 downregulated HMGs, four (CPS1, ARG1,
ASS1, ASL) emerged as lowly expressed in HLE cells.
This cell line also mostly mimicked downregulated small
molecule transporters seen in tumours, e.g. NPC1L1,
SLC25A15/20, SLC2A2, SLC1A1 and SLC7A2 (Fig. 3c).
Indeed, besides urea cycle, downregulated amino acid
HMGs were the best collectively represented alter-
ations in HLE cells. We identified at least 31 of the ~ 50
downregulated amino acid genes in human HCC tissues
that also showed low expression in HLE cells (Fig. 3d,
Additional file 8: Table S7). The downregulated amino
acid-related HMGs are associated with almost all known
amino acids, including phenylalanine, serine/glycine,
glutamate, cysteine and branched chain amino acids
(BCAAs, i.e. valine, isoleucine and leucine) (Fig. 3d).
Well known examples are phenylalanine hydroxylase
(PAH), PHGDH, PSAT1, GLUL, glutamate dehydrogen-
ase 1 (GLUD1), among others. Indeed, the correspond-
ing proteins encoded by many downregulated HMGs
showed low expression in HLE cells, thus reinfor-
cing the gene-level data (Fig. 3c, Additional file 8:
Table S7). Altogether, we reveal that poorly differenti-
ated HCC cells mimic in a cohesive manner the down-
regulation of physiologic liver metabolic components as
seen in the tumour counterpart, with a remarkable simi-
larity in the downregulation of transporters, fatty acid
β-oxidation, urea cycle, and amino acid-related genes.
The dysregulated metabolic pathways correlate with
altered glutamine utilization
We next wanted to uncover metabolite-level alterations
that exist alongside the distinctly expressed metabolic
genes or proteins in the HCC cell lines. To this end, we
considered carbon metabolism, with emphasis on glyco-
lytic pathway, TCA cycle and amino acid metabolism
(Fig. 4a). Regarding glycolysis, both cell lines substan-
tially mimic the expression pattern of key enzymes/
transporters frequently altered in tumours (Fig. 4a), indi-
cating that these cells employ different routes to pre-
serve their glycolytic needs. On the contrary, as
mentioned earlier, the downregulation of genes/proteins
in amino acid metabolism was a more striking alteration
in HLE cells consistent with human data. In perspective,
besides higher expression of glutaminase (GLS) in HLE,
this cell line showed a low expression of GLS2, GLUD1,
GLUL in glutamine metabolism, PHGDH and serine
hydroxymethyltransferase (SHMT1/2) in serine pathway,
and transamination mediators (e.g. GOT1 and GPT1) as
in patients’ datasets. Further, although HLE cells express
a higher level of citrate synthase (CS), they lowly ex-
press MPC1 as noted earlier and also several TCA cycle
enzymes as seen in patients datasets (Fig. 4a–b, Additional
file 8: Table S7).
To gain clinically relevant insight on the overlap be-
tween carbon metabolism genes/enzymes and their associ-
ated metabolites, we next sort to determine metabolite-
level changes that exist in human HCC tissues. For this,
we referred to two tissue-based studies that together ana-
lysed 78 paired HCC samples [17, 18]. Interestingly, these
studies demonstrated that the human HCC tissues have
low glucose, elevated lactate [18], and low TCA cycle in-
termediates (e.g. succinate, fumarate and malate) [17, 18].
In contrast, human HCC tissues showed a high level of
several amino acids, namely glutamine, glutamate, aspar-
tate, methionine, serine, phenylalanine, tyrosine, and
BCAAs [17, 18], indicating that altered amino acid genes/
proteins also reflect at the metabolite level. Similar to hu-
man HCC tissues, HUH7 and HLE cells showed low intra-
cellular level of TCA cycle intermediates compared to
other metabolites like lactate, glutamine and glutamate
(Fig. 4c). Compared to HUH7, HLE cells showed a higher
level of glycolytic intermediate lactate (> 2 fold), as well as
amino acids (e.g. methionine, glycine, glutamate and glu-
tamine) (Fig. 4c), thus more closely portray the
metabolite-level alterations seen in human HCC tissues.
Glucose and glutamine are two main metabolites
known to be preferentially used by cancer cells [19].
Tracing their carbon distribution is a standard approach
for elucidating intracellular metabolic activities in cancer
[20]. We observed that glucose-derived carbon in glyco-
lytic intermediates (pyruvate and lactate) is almost indis-
tinct between both cell lines, albeit slightly higher in
HLE cells (Fig. 4d). Serine – an amino acid produced de
novo from glycolytic intermediate 3-phosphoglycerate [21,
22], and whose pathway enzymes are low in HLE cells
(Fig. 4a) – displayed a lower glucose-derived carbon in
this cell line. Similar readout was observed in glycine,
which lie downstream of serine (Fig. 4d). We found
striking differences between HUH7 and HLE cells
when examining the contribution of glucose or
glutamine-derived carbon to metabolites in the TCA cycle
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and transamination reaction. In HLE cells, the average
glutamine carbon enrichment was about 80% for interme-
diates of TCA cycle [e.g. alpha ketoglutarate (αKG), mal-
ate] and transamination (glutamate and aspartate). This
proportion is substantially higher compared to ~ 40% en-
richment for the same metabolites in HUH7 cells (Fig.
4e). Citrate and succinate also showed ~ 2× higher
glutamine-derived carbon enrichment in HLE than HUH7
cells (Fig. 4e), altogether suggesting a profound reli-
ance on glutamine to sustain TCA cycle in the cell
line more closely mimicking human HCC profile.
Unlike glutamine, the glucose-carbon contribution
to most TCA cycle metabolites is on average ~ 35%
in HUH7 compared to ~ 5% in HLE (except citrate,
~ 25%). These data reveal that HUH7 cells support
TCA cycle by proportionately using both glucose
and glutamine, whereas altered amino acid processes
in HLE cells align with a reliance on extracellular
glutamine for enriching intermediates of TCA cycle,
and aspartate in transamination pathway.
Altered glutamine utilization is a selectively targetable
metabolic vulnerability
Targeting metabolism has shown promising prospects in
cancer therapy [23–25]. We treated HUH7 and HLE cell
Fig. 4 Metabolomic profile of the HCC cell lines. a Schematic representation of metabolic enzymes differentially expressed in intermediary pathways.
In red and ↑ are those higher in HLE cells, while ↓ are lower compared to HUH7 cells. 3-PG – 3-phosphoglycerate; Pyr – pyruvate; OAA – oxaloacetate;
αKG – alpha ketoglutarate; Asp – aspartate; Ala – alanine, Glu – glutamate; Gln – glutamine. b qPCR data showing relative mRNA level of notable
metabolic genes in intermediary metabolism. Arrows indicate the direction of their consistent expression in human HCC microarray datasets as
previously reported [13]. c Intracellular metabolites in HUH7 and HLE cells as measured after 24 h, in triplicates. Cit – citrate, Succ – succinate, Fum –
fumarate, Mal – malate, Cys – cysteine, Ser – serine, Gly – glycine, Lact – lactate; a.u - arbitrary unit. d Isotope tracing data showing glucose/glutamine-
derived carbon contribution to metabolites in glycolysis and serine pathway, after 24 h. e Isotope tracing data showing glucose/glutamine carbon
contribution to TCA cycle and transamination metabolites after 24 h. Bars represent mean ± SD of triplicate analysis
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lines in parallel with thirteen drugs acting on various
metabolic pathways (Additional file 1: Figure S4a) to de-
termine their selective proliferative response to meta-
bolic perturbation. Of the tested drugs, metformin
(complex I inhibitor), oligomycin (ATP synthase inhibi-
tor), and BPTES (a glutaminase inhibitor) exerted more
anti-proliferative effect on HUH7 than in HLE cells
(Fig. 5a). Glucose deprivation, or treatment with 2-deoxy-
glucose (2DG), suppressed the proliferation of both cell
lines, although more profoundly in HLE cells as also ob-
served in the other poorly differentiated cell line, HLF
(Fig. 5a, Additional file 1: Figure S4b). Simvastatin
(HMGCR inhibitor) and UK5099 (MPC inhibitor) both
exerted more anti-proliferative effect on HLE compared
to HUH7 cells. Treatment with methionine sulfoximine
(MSO, inhibitor of GLUL), epigallocatechin gallate (EGCG,
inhibitor of GLUD1), and aminooxyacetate (AOA, pan-
transaminase inhibitor) did not produce a selective re-
sponse in the cell lines (Fig. 5a).
Asparaginase is an enzyme clinically used for the treat-
ment of acute myeloid leukemia [25], and was previously
reported to deplete glutamine availability in HEPG2 cells
[26]. Asparaginase selectively inhibited HLE cell prolifera-
tion with no tangible effect on HUH7 cells (Fig. 5a).
Fig. 5 Phenotypic response to metabolic perturbation in HCC cell lines representing opposite tumour differentiation grades. a MTT proliferation
assay showing response of the HCC cells to metabolism-targeting compounds or glucose/glutamine deprivation. ASPN – Asparaginase (0.5 U),
Rotenone (0.25 μM), 2DG – 2-deoxy-glucose (5 mM), UK5099 (10 μM), AOA – Aminooxyacetate (1 mM), Simvastatin (2.5 mM), DCA –Dichloroacetate
(5 mM), Metformin (5 mM), Oligomycin (1 μM), MSO – Methionine sulfoximine (2 mM), BPTES (5 μM) and EGCG (50 μM). Duration of treatment or
deprivation is 48 h, except ASPN (72 h) and the cells were treated in parallel, each normalized to its untreated/control group. Bars
indicate mean ± SD, and representative of at least 2 experimental observations (n = 4 per group). b MTT proliferation assay showing a selective
antiproliferative effect of CB-839 (glutaminase inhibitor) on HLE cells over 48 h (n = 4 per group). CM – complete medium; UT – untreated,
MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. c A scheme summarizing the differentiation status of HCC cell lines,
examples of human HCC tissue-derived metabolic genes mimicked by the respective cell lines, the accompanying metabolomics profile,
and differential response to metabolic perturbation. w/o – without: refers to extracellular glutamine
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Similarly, the withdrawal of extracellular glutamine (i.e.
from culture media) caused a drastic and selective sup-
pression of HLE cell proliferation (> 50% reduction in
48 h) and this effect was more obvious in the poorly
differentiated- compared to the well-differentiated cell
lines (Additional file 1: Figure S4c). We tested CB-839,
a glutaminase inhibitor shown to mimic glutamine
withdrawal in triple negative breast cancer cells [27].
As anticipated, CB-839 selectively inhibited HLE cell
proliferation (Fig. 5b). These data show that the tumour
molecular alterations displayed by the poorly differenti-
ated cell lines (Fig. 5c) co-exist with inherent metabolic
vulnerabilities like glutamine dependency that may lead
to the identification of selectively druggable pathways
in human liver cancer.
Discussion
Recent studies have provided evidence of profound
metabolic alterations in human liver cancer [13, 28–
33]. HCC cell lines are among a plethora of preclinical
experimental models (e.g. mice, organoids) that can
enable basic and translational studies to delineate the
relevance of altered metabolism, and the prospects of
selective inhibition of biochemical processes in liver
cancer. However, a critical but so far largely un-
answered question is the extent to which experimental
models mimic the metabolic features of liver tumours.
In this study, we focused on the expression pattern
of metabolic genes as it offers the advantage of
broad pathway coverage, reflects tumour biochemical
activities [34], and predicts clinical outcome in cancer
datasets, HCC inclusive [13, 34]. Proteomics and
metabolomics analyses were integrated to enable a
multi-level insight on the tumour molecular alterations
depicted by HCC cell lines. We placed greater em-
phasis on the poorly differentiated cell lines as they
possess several known cancer phenotypes.
Our observation is that the cell lines representative of
well (e.g. HUH7) and poorly differentiated (e.g. HLE)
HCC subclasses, both, mimic the expression pattern of
human HCC-derived metabolic genes (HMGs) (see sum-
mary in Fig. 5c). When compared, HLE cells strongly dis-
play a low expression of about 150 downregulated HMGs,
notably involved in fatty acid β-oxidation, urea cycle, mol-
ecule transport, and amino acid metabolism. These alter-
ations might be pivotal for HCC progression, given
that this cell line possess more tumourigenic phenotype,
e.g. higher migratory and proliferative capabilities. In
addition, metabolic alterations in HLE cells correlate with
other striking features, including a dependency on extra-
cellular glutamine for proliferation, higher GLS expres-
sion, intracellular lactate, ATP, amino acids, as well as
a higher sensitivity to metabolism-targeting drugs (e.g.
asparaginase, CB-839, simvastatin). Of note, elevated
lactate and amino acids have been shown in human
HCC tissues [17, 18]. Further, profound downregulation
of metabolic genes in HCC tissues, as seen in HLE cells,
has been reported in other multi-omics data analyses stud-
ies, including TCGA liver cancer project [28, 29]. This
downregulation of metabolic genes has been attributed to
mutation or hypermethylation [29]. Strikingly, three specific
metabolic genes implicated by the TCGA (i.e. ALB, APOB,
CPS1) are all lowly expressed in HLE cells. Taken to-
gether, our findings on the metabolic profiles shared
between tumours and the poorly differentiated cell
lines support the notion that these cells could be im-
portant surrogates for clinically-relevant HCC metab-
olism studies.
While poorly differentiated cell lines more closely
mimic human HCC profiles, the well-differentiated cells,
exemplified by HUH7 cells, also showed striking resem-
blance to human tumours. For example, considering
gene or protein expression differences, we identified al-
most 100 upregulated HMGs more expressed in HUH7
than in HLE cells. These upregulated HMGs are mostly
involved in lipogenesis, small molecule transport, gly-
can-, membrane lipid- and cholesterol metabolism. Fur-
thermore, with the exemption of GLS (more expressed
in HLE cells), few amino acid-related genes upregulated
in HCC tissues (e.g. GLUL, ASNS, PSPH, ALDH18A1
and PYCR1) are more expressed in HUH7 cells. It is
therefore difficult to exclude that the well-differentiated
cell lines also display tumour molecular signatures. Ra-
ther, given that these cell lines are low migrating, low
proliferating and are known to be more hepatocyte-like
[4], we believe they indicate a breadth of novel metabolic
alterations that either exist exclusively, or are initiated,
at the early stages of liver cancer. At the metabolic
phenotypic level, HUH7 cells do not rely on extracellular
glutamine to drive their proliferation.
Warburg effect (i.e. aerobic glycolysis) is a known
metabolic feature of cancer [25]. However, HLE and
HUH7 cells did not clearly differ in their glucose carbon
flux to glycolytic end-product lactate. Both cell lines are
also sensitive to 2DG, which inhibits the first step in gly-
colysis, i.e. the hexokinase-catalysed phosphorylation of
glucose to glucose-6-phosphate. Thus, it is noteworthy
that both cell lines differentially express glycolytic en-
zymes (e.g. HK1 and LDHA/B are more expressed
in HLE cells, whereas HK2 and PKM are higher in
HUH7 cells). Such distinct expression of crucial en-
zymes could enable an understanding of how human
HCC fulfil glycolytic requirements at the early and ad-
vanced stages. Also noteworthy is a major distinction in
the use glucose and glutamine for TCA cycle enrich-
ment by the HCC cell lines. Whereas HUH7 cells take
advantage of glucose and glutamine to fuel TCA cycle
intermediates, HLE cells rely extensively on glutamine
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to support TCA cycle and aspartate. This data further
supports the resemblance of HLE cells to tumours as
glutamine dependency has been observed in in vitro and
in vivo liver cancer studies [26, 35]. Consistent with our
data, prior studies have shown that glutamine sustains
TCA cycle [23, 36, 37], and intracellular aspartate pool
[38], with an overall phenotypic impact on cell prolifera-
tion. The support of aspartate production by glutamine
is also biologically important in cellular respiration [39,
40]. Thus, we highlight altered glutamine metabolism as
a metabolic vulnerability that could be exploited to-
wards a selective treatment of HCC.
Beyond identifying resemblance to tumour metabolic
profile, our study uncovered other altered targets in the
cell lines that could be relevant signatures in HCC. For
example, BASP1, LDHB, CD44 (high in HLE) and
APOA1, ASGR1, ITIH2, AGT, AFP (high in HUH7 cells)
emerged as the most consistently top targets (i.e. within
top 100 genes in poorly differentiated cells, 3 datasets,
and top 20 proteins in HLE relative to HUH7 cells). The
impact of these candidates on HCC metabolic fate is
currently unclear. Of note, besides AFP and GPC3
which are highly studied biomarkers for early HCC de-
tection [16], CDH1, ALB and EPCAM are highly
expressed in HUH7 cells. This cell line also express a high
level of many metabolic targets consistently upregulated
in HCC patients microarrays (e.g. AKR1B10, SQLE, LYZ,
PLCB1) [13], thus raising the question of whether HUH7
could be a crucial surrogate for identifying novel HCC
metabolic biomarkers. On the other hand, higher expres-
sion of HRAS, NRAS, APC, HFE, MMP9, and a high en-
richment of MAPK/RAS, NFKB, and TNF signaling
pathways are all evident in HLE cells as often seen in can-
cer. Prospective hypotheses could interrogate the potential
contribution of such enriched pathways in modulating
HCC metabolism and progression.
Conclusions
In light of the growing relevance of genomics in refining
clinical HCC subclasses and therapeutic prospects
[1, 2, 41], we identify for the first time, a set of hu-
man HCC-derived metabolic genes concordantly or
discordantly expressed in vitro. Taken together with
the metabolite level changes that coexist with these
gene alterations, our findings provide useful insights
that could lead to future identification of HCC sub-
classes with unique nutrient requirements. This will
facilitate the prospects of targeting metabolism for
HCC therapy, and pave way for delineating meta-
bolic enzymes that are biomarkers or also indispens-
able drivers of HCC. Importantly, our work will
guide the selection of suitable experimental models
for the translational studies of specific metabolic
pathway alterations seen in human liver cancer.
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